Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from China Bozza Development Holdings Limited ( (HK:1069) ).
China Health Technology Group Holding Company Limited has announced the appointment of Mr. Li Zhiliang as the CEO of its subsidiary, Genmao (Shenzhen) Biotechnology Co., Ltd. Mr. Li brings over 22 years of experience in the acer truncatum industry and has been involved in national projects and standards related to acer truncatum. His appointment is expected to enhance the company’s technological capabilities and brand influence, contributing to long-term shareholder value.
More about China Bozza Development Holdings Limited
China Health Technology Group Holding Company Limited operates in the biotechnology sector, with a focus on the development of the entire industrial chain of acer truncatum, particularly in the functional food and oil market.
YTD Price Performance: -2.50%
Average Trading Volume: 1,760,747
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$34.37M
Find detailed analytics on 1069 stock on TipRanks’ Stock Analysis page.